Trial Profile
Efficacy and safety of sequential everolimus and sunitinib treatment in pancreatic metastatic well-differentiated neuroendocrine tumours resistant to prior treatments
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Jul 2018
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Sunitinib (Primary)
- Indications Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- 24 Jul 2018 New trial record